

Clean Version of the Claims

1. At least one isolated mammalian anti-Dengue virus antibody, comprising at least one variable region comprising the amino acid sequence set forth in SEQ ID NOS: 3 or 4.

2. An antibody according to Claim 1, wherein said antibody binds Dengue virus NS-1 protein.

3. An anti-Dengue virus antibody according to Claim 1, wherein said antibody binds at least one Dengue virus NS protein.

4. (cancelled) An isolated nucleic acid encoding at least one mammalian anti-Dengue virus antibody having at least one variable region comprising the amino acid sequence set forth in SEQ ID NOS: 3 or 4.

5. (cancelled) An isolated nucleic acid vector comprising an isolated nucleic acid according to Claim 4.

6. (cancelled) A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid according to Claim 5.

7. (cancelled) A host cell according to Claim 6, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

8. (cancelled) A method for producing at least one anti-Dengue virus antibody, comprising translating a nucleic acid according to Claim 4 under conditions in vitro, in vivo or in situ, such that the anti-Dengue virus antibody is expressed in detectable or recoverable amounts.

9. A composition comprising at least one isolated mammalian anti-Dengue virus antibody having at least one variable region comprising an amino acid sequence set forth in SEQ ID NOS: 3 or 4, and at least one pharmaceutically acceptable carrier or diluent.

10. A composition according to Claim 9, further comprising at least one composition comprising an effective amount of at least one compound or protein selected from at least one of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.

11. (currently amended) A method for diagnosing or treating a Dengue virus-related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody of claim 1, with, or to, said cell, tissue, organ, patient or animal.

12. A method according to Claim 11, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

13. A method according to Claim 11, wherein said contacting or said administering is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

14. A method according to Claim 11, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or protein selected from at least one of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.

15. A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody having at least one variable region comprising SEQ ID NOS: 3 or 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

16. An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of at least one isolated mammalian anti-Dengue virus antibody having at least one variable region comprising SEQ ID NOS: 3 or 4.

17. The article of manufacture of Claim 16, wherein said container is a component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic,

intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery device or system.

18. (cancelled) A method for producing at least one isolated mammalian anti-Dengue virus antibody having at least one variable region comprising SEQ ID NOS: 3 or 4, comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody.

19. At least one anti-Dengue virus antibody produced by a method according to Claim 18.

20. At least one isolated mammalian anti-Dengue virus antibody, comprising either (i) all of the heavy chain complementarity determining regions (CDR) amino acid sequences of SEQ ID NO: 3; or (ii) all of the light chain CDR amino acids sequences of SEQ ID NO: 4.

21. A Dengue virus antibody according to Claim 20, wherein said antibody binds a Dengue virus NS protein.

22. A Dengue virus antibody according to Claim 20, wherein said antibody binds at least one Dengue virus NS 1 protein.

23. (cancelled) An isolated nucleic acid encoding at least one isolated mammalian anti-Dengue virus antibody either (i) all of the heavy chain CDR amino acid sequences of SEQ ID NO: 3; or (ii) all of the light chain CDR amino acids sequences of SEQ ID NO: 4.

24. (cancelled) An isolated nucleic acid vector comprising an isolated nucleic acid according to Claim 4 having the nucleotide sequence set forth in SEQ ID NO: 1 or 2.

25. (cancelled) A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid according to Claim 24.

26. (cancelled) A host cell according to Claim 25, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

27. (cancelled) A method for producing at least one anti-Dengue virus antibody, comprising translating a nucleic acid according to Claim 23 under conditions in vitro, in vivo or in situ, such that the Dengue virus antibody is expressed in detectable or recoverable amounts.

28. A composition comprising at least one isolated mammalian anti-Dengue virus antibody having either (i) all of the heavy chain CDR amino acid sequences of SEQ ID NO: 3; or (ii) all of the light chain CDR amino acids sequences of SEQ ID NO: 4, and at least one pharmaceutically acceptable carrier or diluent.

29. A composition according to Claim 28, further comprising at least one composition comprising an effective amount of at least one compound or protein selected from at least one of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.

30. (currently amended) A method for diagnosing or treating a Dengue virus-related condition in a cell, tissue, organ, patient, animal or population of subjects comprising:
(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody of claim 20, with, or to, said cell, tissue, organ, patient or animal.

31. A method according to Claim 30, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

32. A method according to Claim 30, wherein said contacting or said administering is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

33. A method according to Claim 30, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or protein selected from at least one of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.

34. A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody having either (i) all of the heavy chain CDR amino acid sequences of SEQ ID NO: 3; or (ii) all of the light chain CDR amino acids sequences of SEQ ID NO: 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

35. An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of at least one isolated mammalian anti-Dengue virus antibody having either (i) all of the heavy chain CDR amino acid sequences of SEQ ID NO: 3; or (ii) all of the light chain CDR amino acids sequences of SEQ ID NO: 4.

36. The article of manufacture of Claim 35, wherein said container is a component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery device or system.

37. (cancelled) A method for producing at least one isolated mammalian anti-Dengue virus antibody having either (i) all of the heavy chain CDR amino acid sequences of SEQ ID NO: 3; or (ii) all of the light chain CDR amino acids sequences of SEQ ID NO: 4, comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts nucleic acid molecules encoding said antibody.

38. At least one anti-Dengue virus antibody produced by a method according to Claim 37.

39. At least one isolated mammalian anti-Dengue virus antibody, comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS: 3 or 4.

40. A Dengue virus antibody according to Claim 39, wherein said antibody binds a Dengue virus NS protein.

41. A Dengue virus antibody according to Claim 39, wherein said antibody binds at least one Dengue virus NS 1 protein.

42. An isolated nucleic acid encoding at least one isolated mammalian anti-Dengue virus antibody having at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS: 3 or 4.

43. (cancelled) An isolated nucleic acid vector comprising an isolated nucleic acid according to Claim 42.

44. (cancelled) A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid according to Claim 43.

45. (cancelled) A host cell according to Claim 44, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

46. (cancelled) A method for producing at least one anti-Dengue virus antibody, comprising translating a nucleic acid according to Claim 42 under conditions in vitro, in vivo or in situ, such that the Dengue virus antibody is expressed in detectable or recoverable amounts.

47. A composition comprising at least one isolated mammalian anti-Dengue virus antibody having at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS: 3 or 4, and at least one pharmaceutically acceptable carrier or diluent.

48. A composition according to Claim 47, further comprising at least one composition comprising an effective amount of at least one compound or protein selected from at least one of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.

49. (currently amended) A method for diagnosing or treating a Dengue virus related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody of claim 1, with, or to, said cell, tissue, organ, patient or animal.

50. A method according to Claim 49, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

51. A method according to Claim 49, wherein said contacting or said administering is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

52. A method according to Claim 49, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or protein selected from at least one of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.

53. A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody having at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS: 3 or 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial,

intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

54. An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising at least one isolated mammalian anti-Dengue virus antibody or nucleic acid molecule encoding said antibody, having at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS: 3 or 4.

55. The article of manufacture of Claim 54, wherein said container is a component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery device or system.

56. (cancelled) A method for producing at least one isolated mammalian anti-Dengue virus antibody having at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS: 3 or 4, comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing a nucleic acid molecule encoding said antibody in recoverable amounts.

57. At least one anti-Dengue virus antibody produced by a method according to Claim 56 wherein said nucleic acid molecule comprises SEQ ID NO: 1 or 2.

58. At least one isolated mammalian anti-Dengue virus antibody that binds to the same region of a Dengue virus protein as an antibody comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS: 3 or 4.

59. A Dengue virus antibody according to Claim 58, wherein said antibody binds a Dengue virus NS protein.

60. A Dengue virus antibody according to Claim 58, wherein said antibody substantially neutralizes at least one activity of at least one Dengue virus protein.

61. (cancelled) An isolated nucleic acid encoding at least one isolated mammalian anti-Dengue virus antibody that binds to the same region of a Dengue virus protein as an antibody comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS: 3 or 4.

62. (cancelled) An isolated nucleic acid vector comprising an isolated nucleic acid according to Claim 61.

63. (cancelled) A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid according to Claim 62.

64. (cancelled) A host cell according to Claim 63, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

65. (cancelled) A method for producing at least one anti-Dengue virus antibody, comprising translating a nucleic acid according to Claim 61 under conditions in vitro, in vivo or in situ, such that the Dengue virus antibody is expressed in detectable or recoverable amounts.

66. A composition comprising at least one isolated mammalian anti-Dengue virus antibody that binds to the same region of a Dengue virus protein as an antibody comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS: 3 or 4, and at least one pharmaceutically acceptable carrier or diluent.

67. A composition according to Claim 66, further comprising at least one composition comprising an effective amount of at least one compound or protein selected from at least one of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.

68. (currently amended) A method for diagnosing or treating a Dengue virus related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody that binds to the same region of a Dengue virus protein as the antibody of claim 1, with, or to, said cell, tissue, organ, patient or animal.

69. A method according to Claim 68, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

70. A method according to Claim 68, wherein said contacting or said administering is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

71. A method according to Claim 68, further comprising administering, prior, concurrently or after said step (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or protein selected from at least one of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.

72. A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody or nucleic acid molecule encoding said antibody that binds to the same region of a Dengue virus protein as an antibody comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS: 3 or 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

73. An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising at least one isolated mammalian anti-Dengue virus antibody or nucleic acid molecule encoding said antibody that binds to the same region of a Dengue virus protein as an antibody comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS: 3 or 4.

74. The article of manufacture of Claim 73, wherein said container is a component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery device or system.

75. (cancelled) A method for producing at least one isolated mammalian anti-Dengue virus antibody that binds to the same region of a Dengue virus protein as an antibody comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS: 3 or 4, comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody.

76. At least one anti-Dengue virus antibody produced by a method according to Claim 75.

77. (currently amended) At least one isolated mammalian anti-Dengue virus antibody, comprising at least one human CDR, wherein said antibody specifically binds at least one epitope comprising at least 1-3 amino acids, to the entire amino acid sequence of a Dengue virus NS protein.

78. A Dengue virus antibody according to Claim 77, wherein said antibody binds a Dengue virus NS1 protein.

79. A Dengue virus antibody according to Claim 77, wherein said antibody substantially neutralizes at least one activity of at least one Dengue virus NS protein.

80. (cancelled) An isolated nucleic acid encoding at least one isolated mammalian anti-Dengue virus antibody having at least one human CDR, wherein said antibody specifically binds at least one epitope comprising two or more amino acids of Dengue virus NS1 protein.

81. (cancelled) An isolated nucleic acid vector comprising an isolated nucleic acid according to Claim 80.

82. (cancelled) A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid according to Claim 81.

83. (cancelled) A host cell according to Claim 82, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

84. (cancelled) A method for producing at least one anti-Dengue virus antibody, comprising translating a nucleic acid according to Claim 80 under conditions in vitro, in vivo or in situ, such that the Dengue virus antibody is expressed in detectable or recoverable amounts, wherein said nucleic acid molecule comprises SEQ ID NO: 1 or 2.

85. A composition comprising at least one isolated mammalian anti-Dengue virus antibody having at least one human CDR, wherein said antibody specifically binds at least one epitope comprising two or more amino acids of Dengue virus NS1 protein, and at least one pharmaceutically acceptable carrier or diluent.

86. A composition according to Claim 85, further comprising at least one composition comprising an effective amount of at least one compound or protein selected from at least one of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.

87. (currently amended) A method for diagnosing or treating a Dengue virus related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody of claim 77, with, or to, said cell, tissue, organ, patient or animal.

88. A method according to Claim 87, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

89. A method according to Claim 87, wherein said contacting or said administering is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

90. A method according to Claim 87, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or protein selected from at least one of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.

91. (currently amended) A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody or a nucleic acid molecule encoding said antibody, having at least one human CDR, wherein said antibody specifically binds at least one epitope comprising at least 1-3 amino acids, to the entire amino acid sequence of a Dengue virus NS protein, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic,

intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

92. An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising at least one isolated mammalian anti-Dengue virus antibody or a nucleic acid molecule encoding said antibody, having at least one human CDR, wherein said antibody specifically binds at least one epitope comprising two or more amino acids of Dengue virus NS1 protein.

93. The article of manufacture of Claim 92, wherein said container is a component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery device or system.

94. (cancelled) A method for producing at least one isolated mammalian anti-Dengue virus antibody having at least one human CDR, wherein said antibody specifically binds at least one epitope comprising two or more amino acids of Dengue virus NS1 protein, comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody.

95. At least one anti-Dengue virus antibody produced by a method according to Claim 94.